TURKU, FINLAND – October 13, 2025 – DelSiTech Ltd, leader in biodegradable silica-based drug delivery technologies, today announced a leadership change.
Effective October 12, 2025, Carl-Åke Carlsson, resigned from his duties as CEO of the company. The Board thanks Carl-Åke for his services to the company. During his tenure, Carl-Åke played an instrumental role in fine-tuning the company’s strategy and building a roadmap for the internal manufacturing capabilities. We wish Carl-Åke the very best in his future endeavors.
The Board has already initiated the search for the next CEO, and the company will announce the successor in due course.
The Board is also very pleased to welcome Martti Hedman as the company’s interim CEO to lead the company into a new and exciting phase. Martti is best positioned to take over this role with nearly 40 years of experience from the pharmaceutical business having held executive positions in the United States, United Kingdom, Germany and Finland. Most recently, Martti served 8 years as the CEO of Colorcon Inc. and 3 years as the CEO of DFE Pharma GmbH. Both companies are global market leaders in their businesses. Martti also serves on the Boards of several life-science companies. As a previous Board member of DelSiTech, Martti is very familiar with the company and its great potential in the development of own proprietary drug portfolio and out-licensing of long-acting, injectable drug delivery technologies to pharmaceutical companies globally.